This study evaluated the in vitro and in vivo performance of antibiotic-releasing porous polymethylmethacrylate (PMMA)-based space maintainers comprising a gelatin hydrogel porogen and a poly(DL-lactic-co-glycolic acid) (PLGA) particulate carrier for antibiotic delivery. Colistin was released in vitro from either gelatin or PLGA microparticle loaded PMMA constructs, with gelatin-loaded constructs releasing colistin over approximately 7 days and PLGA microparticle-loaded constructs releasing colistin up to 8 weeks. Three formulations with either a burst release or extended release in different doses were tested in a rabbit mandibular defect inoculated with Acinetobacter baumannii (2 × 10 7 colony forming units/mL). In addition, one material control that released antibiotic but was not inoculated with A. baumannii was tested. A. baumannii was not detectable in any animal after 12 weeks by culture of the defect, saliva, or blood. Defects with high-dose, extended-release implants had greater soft tissue healing compared to defects with burst release implants, with 8 out of 10 animals showing healed mucosae compared to 2 out of 10 with healed mucosae, respectively. Extended release of locally delivered colistin via a PLGA microparticle carrier improved soft tissue healing over the implants compared to burst release of colistin from a gelatin carrier.
Introduction
Non-porous space maintainers have been previously shown to enhance craniofacial reconstruction by maintaining the bony structure and soft tissue envelope for later bone regeneration. [1] However, implantation of a foreign body into an area where bone has been resected due to trauma or pathology could precipitate an infection due to the presence of oral flora and colonization of the material. Some clinical products, such as polymethylmethacrylate (PMMA)-based bone cements, have incorporated antibiotics for local control of infection [2] [3] [4] [5] [6] . The release of these antibiotics is rapid, and the majority of the loaded antibiotic remains in the cement, rendering them ineffective at long-term infection control. [2] Previous work from our laboratory has utilized particulate delivery systems, such as gelatin and poly(DL-lactic-co-glycolic acid) (PLGA) microparticles, to control the release of antibiotics from porous PMMA-based constructs. [7, 8] The porosity of these constructs was generated by using a carboxymethylcellulose or gelatin hydrogel as a porogen, and the resulting porosity allowed for greater cumulative release of antibiotic. [7] [8] [9] [10] In these studies, colistin, a polypeptide antibiotic, was incorporated into either gelatin or PLGA microparticles. Colistin was selected due to its efficacy against Acinetobacter baumannii, a commonly multi-drug resistant bacterial strain that has been observed to have increased incidence of infection in traumatic combat wounds [11] [12] [13] [14] [15] .
Additionally, because colistin is infrequently used systemically due to nephrotoxicity, it is an ideal choice for local delivery due to both decreased systemic concentrations and increased local concentrations. [16] 5 This study investigated the use of porous PMMA/PLGA/gelatin/colistin constructs as antibiotic-releasing space maintainers by characterizing their release kinetics in vitro and evaluating their efficacy in vivo in a rabbit infected composite tissue defect model. The goal of the study was to assess the effects of antibiotic dose and release kinetics on wound healing, infection clearance, kidney function, and tissue response to the construct.
Materials and Methods

Materials
Poly(DL-lactic-co-glycolic acid) (PLGA) was obtained from Lakeshore Biomaterials (Birmingham, AL) and had a copolymer ratio of 50:50, a weight average molecular weight of 61.1 kDa, and a number average molecular weight of 37.3 kDa as measured by gel permeation chromatography. [7] Colistin sulfate salt was purchased from SigmaAldrich (St. Louis, MO). Poly(vinyl alcohol) (PVA) was 88% hydrolyzed with a nominal molecular weight of 22 kDA and was purchased from Acros Organics (Geel, Belgium).
Surgiflo Hemostatic Matrix (Ethicon, Somerville, NJ) was used as a source of gelatin.
Bone cement was obtained from Depuy Orthopaedics (Smartset HV, Warsaw, IN).
Microparticle Fabrication
PLGA microparticles containing colistin were fabricated as previously described [7] .
Briefly, a water-in-oil-in-water double emulsion solvent extraction technique was used.
The internal phases consisted of colistin dissolved in a solution of 0.4 wt% PVA at a concentration of 325 mg/mL. The oil phase comprised PLGA in methylene chloride at a concentration of 50 mg/mL. The oil phase was added to the internal phase in a ratio of 6 20:1 oil:internal phase and homogenized. The water/oil emulsion was added to the external phase, a solution of 0.4 wt% PVA with 0.5 M NaCl, in a ratio of 10:1 external phase:oil. The solvent was allowed to evaporate for 4 hours, and the particles were washed, lyophilized, and stored at -20°C. Blank microparticles were fabricated with an internal phase of 0.4 wt% of PVA without antibiotic. The entrapment of colistin-loaded microparticles was determined as previously described [7] .
Space Maintainer Fabrication
Gelatin matrix was swollen in a 1:1.9 ratio of solution weight to gelatin weight. The swollen gelatin matrix comprised 30 wt% of the total space maintainer mass. Bone cement was used for all samples in a ratio of 2.11:1 of powder phase to monomer phase as supplied by the manufacturer. To fabricate the space maintainers, the powder phase of the bone cement was first dispersed into the gelatin matrix. The monomer phase of the bone cement was added and mixed, and the space maintainer was molded and allowed to cure.
Colistin was loaded into the constructs using either the gelatin matrix or PLGA microparticles. For groups with colistin loaded into the gelatin matrix, the gelatin matrix was swollen with 150 mg/mL colistin in ddH 2 O in a ratio of 1:1.9 solution weight to gelatin weight. For groups with colistin loaded into the PLGA microparticles, PLGA microparticles comprised 11 wt% of the total mass and were added to the powder phase of the bone cement. For the PLGA High group this 11% consisted entirely of colistinloaded microparticles, while for the PLGA Low group approximately half of the colistinloaded microspheres were replaced with blank PLGA microparticles. Table 1   7 summarizes the groups used for all analyses including the calculated drug content based on the entrapment efficiency for the PLGA groups and the concentration for the Gelatin group. The Gelatin group was formulated such that the burst release of colistin at 6h was approximately equivalent to the total cumulative release of the PLGA High group over the 84d study. Of note, although the weight percentages of each component between groups may differ, each construct contained the same absolute amount of gelatin, PMMA powder, and liquid monomer. Each sample was sterilely aliquoted in sterile containers for intraoperative fabrication and cured in situ.
Colistin Release
The release kinetics of each group containing colistin were determined by high performance liquid chromatogray (HPLC) as previously reported. [7, 8] 
Kidney Function
The kidney function of the rabbits was analyzed at 0, 1 and 5 weeks by measuring plasma creatinine and blood urea nitrogen from blood drawn from the ear vein. The plasma concentrations were measured using an IDEXX Vet Test 8008 (IDEXX Laboratories, Westbrook, ME).
Sample Culture
At 12 weeks postoperatively, the rabbits were euthanized by barbiturate overdose.
A blood sample was taken sterilely from cardiac puncture with 3.8% sodium citrate. The anterior edge of the defect was exposed by sterile dissection. Sterile cotton swabs were used to collect samples from saliva, the anterior edge of the defect, and any abscesses in the craniofacial region. The swabs were cultured at 37°C on tryptic soy agar (BD, Franklin Lakes, NJ) and tryptic soy agar with 5% sheep blood (BD, Franklin Lakes, NJ) for blood samples. Individual colonies were tested for oxidase activity by oxidase reagent (PML Microbiologicals, Wilsonville, OR). The same colonies were smeared on glass slides and stained with Gram's stain. All Gram-negative oxidase-negative colonies were further identified by the API 20 NE kit (bioMerieux, Marcy l'Etoile, France). 11 
Gross Observation
At the time of euthanasia, the right hemimandible was explanted. The mucosa over the defect was classified as healed or non-healed and the other oral mucosa was classified as dehisced or non-dehisced. The mandibles were then placed in 10% neutral buffered formalin for fixation for 72 hours. After 72 hours, the mandibles were transferred to 70% ethanol.
Histology
The mandibles were dehydrated in serial solutions of ethanol (70-100%) and embedded in methylmethacrylate. After complete polymerization, 10 µm sections were cut coronally using an inner circle diamond microtome (Leica, Wetzlar, Germany) and stained with methylene blue and basic fuchsin. Three blinded reviewers scored each specimen according to the scoring system shown in Table 2 to assess the tissue response around the implant and within the pores of the implant. [18] Images were obtained using an AxioImager Z.2 microscope (Zeiss, Oberkochen, Germany).
Statistical Analysis
The colistin released at each timepoint, the MIC of each group, and the creatinine and blood urea nitrogen values were compared using ANOVA with post-hoc analysis by Tukey's honestly significant difference test. The classifications of oral mucosae were compared using the Fisher-Freeman-Halton test with post-hoc analysis by Fisher's exact test. The histological scores of the space maintainers were compared using the Kruskal- 12 Wallis test with post-hoc analysis by the Mann-Whitney U test. An a priori level of significance was set at α=0.05. All analyses were performed using MATLAB (Version R2011B, Natick, MA).
Results
Colistin Release
Colistin was released for up to 8 weeks from the space maintainers in vitro. 
Bacterial Susceptibility
The susceptibility of A. baumannii to colistin, colistin released from the Gelatin, PLGA Low and PLGA High groups was measured as the MIC according to ISO 20776 using the microdilution method. Colistin standard had an MIC of 4.00 ± 0.00 µg/mL. At 13 the 6 hour timepoint, colistin from the Gelatin group had an MIC of 1.67 ± 0.58 µg/mL, from the PLGA Low group had an MIC of 4.00 ± 0.00 µg/mL, and from the PLGA High group had an MIC of 3.33 ± 1.15 µg/mL. At the 39 day timepoint, colistin from the Gelatin group did not inhibit growth as there was no detectable colistin (i.e. no MIC determined), from the PLGA Low group had an MIC of 3.33 ± 1.15 µg/mL, and from the PLGA High group had an MIC of 4.00 ± 0.00 µg/mL. The MICs of each group are not statistically significant from each other (p>0.05).
Animal Care
Surgery was performed on 45 rabbits, with 5 prematurely euthanized animals that
were not included in the analysis. All prematurely euthanized animals had complications unrelated to the treatment but rather due to general problems including unresolved postoperative diarrhea, neurological deficits due to spinal fracture, and unresolved foot wounds. The remaining 40 animals were healthy and were euthanized at 12 weeks postoperatively.
Kidney Function
Mean values for creatinine and BUN levels were within normal range (creatinine: 0.8-1.8 mg/dL; BUN: 10-24 mg/dL) for all animals, and there were no significant differences between groups at each time point (Figure 2 ). Creatinine and BUN remained below the threshold that would indicate acute tubular necrosis due to nephrotoxic systemic levels of colistin. 14 
Gross Observation
In addition to healed (Fig. 3A) and non-healed (Fig. 3B ) mucosal defects, some rabbits exhibited a separate medial mucosal dehiscence as seen in Figure 3C . The black arrows in Figures 3B and 3C indicate exposed implant through non-healed and dehisced mucosae, respectively. Figure 4A shows the number of healed mucosae in each group
and Figure 4B shows the number of dehisced mucosae in each group. There were a significantly greater number of healed mucosae in the PLGA High group compared to the Gelatin group (p<0.05). There were no significant differences between groups for the dehiscences.
Sample Culture
All saliva swabs and 3 defect swabs grew bacteria; however, none of these bacteria proved to be A. baumannii. Colonies grown from saliva swabs were excluded based on Gram stain, oxidase presence, or with the API 20NE kit. No blood swabs grew bacteria. Two defects had abscesses; however, only one grew bacteria, which were gram positive.
Histology
Histological assessment of the space maintainers explanted from mandibles confirmed the presence of healed ( Figures 5A and 5E ) and non-healed ( Figure 5C ) oral mucosae in various samples. Histologic scoring of the tissue-implant interface revealed that the PLGA High group had significantly higher histological scores than the Uninfected group (p<0.05). As seen in Figure 6A and fibrous tissue and bone, respectively, as indicated in Table 2 .
Discussion
This study evaluated porous space maintainers fabricated from clinically available the wound after the short duration of antibiotic delivery, whereas they remain sessile with continued delivery of antibiotics in the extended release groups. [22] For the first time using this model, a dehiscence separate from the intentional mucosal defect was observed. As seen in Figure 3C , these dehiscences were located on the lingual aspect of the mucosa overlying the implant. Because dehiscences were seen in the Uninfected group of this study, these dehiscences were likely not due to the presence of the inoculated bacteria. The primary differences in formulation between the samples in this study and the samples used in previous studies are the use of gelatin as a porogen and the delivery of antibiotics. [9, 10] These dehiscences could therefore be due to the presence of gelatin, colistin, or their combination. Although gelatin cannot be excluded as a cause of dehiscence, it is perhaps a less likely culprit as previous studies have not shown dehiscence when gelatin is implanted in the oral and maxillofacial region, though these studies are not extensive. [23, 24] Previous studies have shown that antibiotics, while intended to target bacteria, can have detrimental effects on viability and function of host cells in vitro. [25, 26] This toxic effect seen in vitro could lead to breakdown of the soft tissue, fenestration, and dehiscence in vivo. It is also possible that the combination of gelatin and colistin may lead to increased local toxicity if the gelatin causes increased tissue exposure to colistin by retaining released colistin in the area.
In addition to efficacy in infection clearance, safety was measured through the analysis of kidney function by plasma concentration of BUN and creatinine. The early discovery of nephrotoxicity with colistin has led to increased research into local delivery of the drug for increased local concentration with decreased systemic exposure. [16, [27] [28] [29] This study showed that with high local delivery to the wound site, the negative systemic effects of colistin administration were avoided. Local delivery strategies may allow for increased application of powerful antibiotics that were previously underused clinically due to severe systemic adverse effects.
Clearance of the infection was also evaluated by cultures of the saliva, blood, and defect at 12 weeks. While three of the defects and all of the saliva swabs grew bacteria, none were identified to be A. baumannii. In the normal rabbit, saliva swabs would culture many different bacteria due to physiologic mucosal colonization. In addition, these bacteria could inoculate and colonize the porosity of the implant through the 18 mucosal defect. This is corroborated by the few defect swabs that did culture bacteria that were not identified as A. baumannii. This finding is consistent with previous studies where increased inflammation in highly porous space maintainers was attributed to colonization of the implant by oral flora. [9] Additionally, a recent study showed that 37% of traumatic injuries resulted in polymicrobial infections. [30] Thus, while the delivery of a single antibiotic is likely inadequate alone to treat such polymicrobial wound infections, the animal model used in this study presents a complex environment very similar to the targeted problem area.
Although there were significant differences in gross wound healing between the PLGA High and Gelatin groups, no significant difference was observed between the two groups in the histological response of the tissue-implant interface and the tissue within the pores. As seen in Figure 6A , many of the samples received scores of 2 for a mature fibrous capsule; however, for several of these samples, there was a layer of inflammatory cells between the fibrous capsule and the implant as shown in Figure 5B . This has been previously demonstrated to be due to continued release of proinflammatory molecules being released from the implant resulting in the invasion by inflammatory cells. [31] Inflammatory molecules from bacterial colonization or the degradation products of PLGA or gelatin may be released from the implant at late time points, resulting in the recruitment of inflammatory cells. These differences are reflected in the organization of the fibrous capsule for implants from the current study. Finally, there are several instances of direct bone-implant contact either at the interface or in the pores of the implant, as shown in Figure 5D , illustrating that after 12 weeks, there is some growth of bone around and in the implant. 19 This study would be strengthened by the use of infected untreated controls to verify that an initial infection with A. baumannii was achieved. However, an untreated infection in the craniofacial region presents animal welfare concerns, including pain and discomfort, and was accordingly not included in the study. There are several important strengths to this study. First, the formulations used in this study allow for comparison of the effects of extended release and burst release of colistin on gross and microscopic tissue healing. Second, dose effects of the extended release formulation were also investigated by using a high and low dose loading of colistin-loaded PLGA microparticles into the constructs. Last, the measurement of BUN and creatinine as well tissue within the pores of the implants using the scoring system described in Table 2 .
* indicates a significant difference between the Uninfected and the PLGA High groups for the tissue-implant interface score (p < 0.05). 
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